BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?
Gearing Up For August Approval
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.
You may also be interested in...
The expected launch of BioMarin's Roctavian for hemophilia A is expected to heighten the profile of expensive gene therapies on payers' radar. Specialty drug costs are expected to continue to grow in 2021.
The company lowered revenue guidance due to COVID-19, but announced a new brand name, Roctavian, for its hemophilia A gene therapy, which it said remains on track for FDA approval later this year.
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.